AI in pharmacovigilance market to hit $1.88 billion by 2030

The global artificial intelligence market in pharmacovigilance is projected to grow from $0.77 billion in 2025 to $1.88 billion by 2030, as drugmakers and regulators push for faster safety monitoring and better adverse-event detection. North America led in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - AI is changing drug safety monitoring by helping teams detect adverse reactions faster and with more accuracy. - The market’s projected growth signals rising demand for automated pharmacovigilance as adverse event reporting expands and compliance rules tighten.

What happened: - The Business Research Company projected the global AI in pharmacovigilance market will rise from $0.77 billion in 2025 to $0.92 billion in 2026. - The market is forecast to reach $1.88 billion by 2030. - The report puts the market on a 19.6% CAGR through the forecast period. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - AI in pharmacovigilance uses machine learning, natural language processing and data analytics to identify, assess, monitor and prevent adverse drug reactions and other safety issues. - The technology automates analysis of structured and unstructured healthcare data. - Automation helps speed up safety-signal detection, improve risk assessment and strengthen regulatory reporting. - Growth in the market has been supported by higher adverse drug reaction reporting requirements, broader regulatory frameworks, wider use of electronic health records, more complex clinical trial data and early rule-based drug safety systems. - Future growth is expected to come from AI-powered drug safety surveillance, more real-world healthcare data, tighter compliance standards, better predictive analytics and more multi-source clinical data integration. - Key trends include automated literature screening, real-world evidence analytics, generative AI in regulatory reporting, automated case intake and workflow processing, and cross-border regulatory harmonization. - The AI in pharmacovigilance market analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report’s 2026 update adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and updated graphics and tables. - A free sample of the report is available here. - The full report is available here.

Between the lines: - The forecast points to a shift from manual safety review toward AI-supported workflows in regulated healthcare settings. - Rising adverse event volumes and broader reporting obligations are making traditional review methods harder to scale. - The strong regional split suggests mature markets are adopting first, while digitization and pharma growth are accelerating demand in newer markets.

What's next: - AI adoption in pharmacovigilance is likely to expand as regulatory expectations for speed, accuracy and traceability increase. - Generative AI and automated workflows may become more central to safety reporting and case processing. - Cross-border data exchange rules and harmonized reporting standards could shape which tools scale globally.

The bottom line: - Pharmacovigilance is becoming a data-and-automation problem, and AI is positioned to be the core response.